About InterMED-Rx
The older InterMED-Rx site is now closed. It has be replaced by this web application.
Please note that you will have to register again if you were a member of the old site.
You are consulting the production version of the new InterMED-Rx web application which has replaced the older website on January 1st 2011.
With a unique method of identifying P450 interactions and fact based NON-CYP interactions InterMED-Rx is the first 2nd generation DDI software.
If you were a member of the older website you will have to re-register. Note that you will be required to make a payment of $119.99 CAD + applicable taxes to complete your registration and start using the application.
Please take a few minutes to provide feedback.
The use of therapeutic regimes that rely on polypharmacy entail higher risks of drug interactions. Consequently, these interactions must be monitored more closely by health professionals.
The InterMED-Rx web application provides health professionals with a user-friendly tool at the cutting edge of scientific knowledge. This site provides a better grasp of drug interactions related to the cytochrome P450 superfamily.
Jacques Turgeon, B.Pharm., Ph.D.
Cytochrome P450 Theoretical Notions
The cytochrome P450 is a superfamily of enzymes whose main role is to transform liposoluble substances into more hydrosoluble substances. This action typically favours the elimination of substances perceived as potentially toxic. It is important to note that the roughly 35 cytochrome P450 isoenzymes found in human beings contribute both to the biotransformation of exogenous and endogenous substances and to the synthesis of endogenous compounds.
In this section of our site, health professionals have access to theoretical notions about the underlying principles of metabolism, the cytochrome P450 superfamily and the particular characteristics of certain isoenzymes. In addition, this section contains theoretical notions about membrane transporters, the P-glycoprotein in particular. These notions make up the basic material of a course (PHM-6508) in the professional continuing education program offered by Université de Montréal's Faculty of Pharmacy.
P-450 Table
This section of our site provides an original and unique listing of the inhibitors, substrates and inducers of the cytochromes P450 principal isoenzymes. The presentation of substrates in three affinity categories makes it possible to predict which one will lead to a modification of the elimination capacities of another substrate. The selection of a given substrate calls up a list of pre-selected references that provide users with scientific data relevant to their decision.
As of January 1st 2011
InterMED-Rx migrates to a new web application. With even more data and information available than before (bioavailability, un-changed urinary excretion, non-P450 interactions) and together with the best clinical information system we are empowering clinicians to use their clinical judgment in order to take charge of patients' drug interactions.
October, 2010
InterMED-Rx certifies that Artefact Informatique (Division of IBM/LGS) has completed integration of the InterMED Web-Service and its functionalities. As such hospital pharmacies that use the SyPhaC suite of products may now start benefiting from the use of the InterMED-Rx Therapeutic Advisor.
November, 2009
HLHL has selected InterMED-Rx as its drug-interaction software. As such, InterMED-Rx was integrated into the pharmacy management system at Louis H. Lafontaine Hospital in Montreal, QC.
March, 2008
IUGM selects InterMED-Rx as drug-interaction software... partially integrated by CGSI into GespharX 8, InterMED-Rx was installed for trial and demo purposes at IUGM, a Montreal geriatric hospital.
November, 2007
InterMED-Rx launches clinical drug-interaction software... Used as a stand-alone module or integrated into their clinical information systems, hospital and retail pharmacies may now benefit from the use of the most advanced DDI software available.